| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | 125,712 | 86,363 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 24,310 | 146,179 |
| Cash and cash equivalents at beginning of period | 36,968 | - |
| Cash and cash equivalents at end of period | 61,278 | - |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)